Lv1
60 积分 2024-11-01 加入
Second‐line chimeric antigen receptor T‐cell therapy versus standard of care in relapsed or refractory large B‐cell lymphoma: A systematic review and meta‐analysis
4天前
已完结
[Expert consensus on the management practice of CD19 CAR-T cell therapy for B-cell lymphoma in China (2025 edition)]
1个月前
已关闭
Axicabtagene Ciloleucel in Large B-Cell Lymphoma
1个月前
已完结
Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era
1个月前
已完结
Chimeric antigen receptor T‐cell therapy combined with autologous stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large B‐cell lymphoma patients: A single‐center, retrospective, cohort study
1个月前
已完结
The promise of immunotherapy for central nervous system tumours
2个月前
已完结
Advances in Primary Central Nervous System Lymphoma
2个月前
已完结
Primary central nervous system lymphoma
2个月前
已完结
Advances and challenges in the treatment of primary central nervous system lymphoma
2个月前
已完结
Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study
2个月前
已完结
皖公网安备34019202002308
